NCT06729047

Brief Summary

Post-dural puncture headache (PDPH) or spinal (or post-spinal) headache is one of the most common side effects of spinal anesthesia, with an incidence of 6-36%. The incidence of this complication was reported to be 76-85% after accidental dural puncture in epidural anesthesia. It usually starts within several hours after spinal anesthesia, but sometimes it can be delayed for up to 2 weeks, which usually resolves within a few days

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
330

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Dec 2024

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 8, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 11, 2024

Completed
4 days until next milestone

Study Start

First participant enrolled

December 15, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2025

Completed
4 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 5, 2025

Completed
Last Updated

December 11, 2024

Status Verified

December 1, 2024

Enrollment Period

11 months

First QC Date

December 8, 2024

Last Update Submit

December 8, 2024

Conditions

Keywords

Neostigmineketorolac

Outcome Measures

Primary Outcomes (1)

  • postdural puncture headache

    the incidence of occurrence of PDPH in patients undergoing infraumbilical surgeries under SA.

    1 week

Study Arms (3)

Group C

PLACEBO COMPARATOR

patients will receive placebo (normal saline)

Drug: normal Saline

Group N

ACTIVE COMPARATOR

patients will receive neostigmine (40 μg/kg) plus atropine (20 μg/kg)

Drug: Neostigmine

Group K

ACTIVE COMPARATOR

patients will receive ketorolac (0.5 mg/kg)

Drug: Ketorolac

Interventions

patients will receive placebo (normal saline)

Group C

patients will receive neostigmine (40 μg/kg) plus atropine (20 μg/kg)

Group N

patients will receive ketorolac (0.5 mg/kg)

Group K

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • BMI less than 35 kg/m2
  • Scheduled for infraumbilical surgeries
  • American Society of Anesthesiologists (ASA) physical status: I and II

You may not qualify if:

  • ASA physical status more than II.
  • History of allrgic response to local anaesthetics or any of the medications used in the study
  • Patients with cognitive impairment
  • pregnancy
  • Basal body temperature of more than 38°C or less than 36°C
  • BMI more than 35 kg/m2

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of medicine, Assiut University, Assiut, Egypt,

Asyut, 71515, Egypt

Location

Related Publications (3)

  • Kamm K, Forderreuther S. [Post-dural puncture headache]. Schmerz. 2021 Apr;35(2):139-149. doi: 10.1007/s00482-021-00540-x. Epub 2021 Mar 16. German.

    PMID: 33725180BACKGROUND
  • Ljubisavljevic S, Zidverc Trajkovic J. Postdural puncture headache leads to clinical worsening of pre-existing chronic headache. J Clin Neurosci. 2020 May;75:30-34. doi: 10.1016/j.jocn.2020.03.043. Epub 2020 Mar 26.

    PMID: 32223975BACKGROUND
  • Ahmadzade Z, Golparvar M, Sepiani S. Evaluation of the Preventive Effects of Neostigmine Plus Atropine on Post-Dural Puncture Headache. Adv Biomed Res. 2023 May 15;12:119. doi: 10.4103/abr.abr_81_22. eCollection 2023.

    PMID: 37434934BACKGROUND

MeSH Terms

Conditions

Post-Dural Puncture Headache

Interventions

Saline SolutionNeostigmineKetorolac

Condition Hierarchy (Ancestors)

Headache Disorders, SecondaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical PreparationsPhenylammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic ChemicalsOnium CompoundsIndomethacinIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Central Study Contacts

Ghada Abo Elfadl, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

December 8, 2024

First Posted

December 11, 2024

Study Start

December 15, 2024

Primary Completion

November 1, 2025

Study Completion

November 5, 2025

Last Updated

December 11, 2024

Record last verified: 2024-12

Locations